Episomal Vector iPS Cell Reprogramming Efficiency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for establishing induced pluripotent stem (iPS) cells, particularly from blood cells, face low efficiency and safety concerns due to the use of viral vectors, and episomal vectors struggle with efficient establishment and vector removal, limiting their clinical application.
Innovation Solution
The use of episomal vectors containing nucleic acids encoding nuclear reprogramming factors and EBNA-1, along with an inhibitor of p53 function, significantly enhances iPS cell establishment efficiency, especially from blood cells, by introducing these vectors into somatic cells to promote efficient and safe production of iPS cells suitable for regenerative medicine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors (retrovirus, lentivirus) are used to introduce reprogramming factors, then transgene efficiency and iPS cell establishment efficiency are improved, but safety problems arise due to chromosomal incorporation
Solution Approach 1:
The patent uses episomal vectors that maintain reprogramming factors as separate extrachromosomal elements rather than integrating them into the host genome. This segmentation approach allows high expression efficiency while avoiding the safety risks of chromosomal incorporation, as the vectors replicate independently and can be removed after reprogramming is complete
Solution Approach 2:
The patent introduces EBNA-1 as an intermediary protein that enables episomal vectors to replicate and maintain themselves in human cells without integrating into chromosomes. This intermediary mechanism allows the system to achieve viral-level efficiency while maintaining the safety advantages of non-integrating vectors
2Object-affected harmful factors
If nonviral episomal vectors are used to avoid chromosomal incorporation, then safety is improved, but iPS cell establishment efficiency becomes low
Solution Approach 1:
The patent merges the safety features of nonviral episomal vectors with the high efficiency of viral vectors by combining multiple reprogramming factors (Oct3/4, Sox2, Klf4, L-Myc, Lin28, and Glis1) into episomal vector constructs that replicate efficiently in human cells through the EBNA-1 mechanism, achieving both safety and high establishment efficiency
Solution Approach 2:
The patent optimizes multiple parameters including the combination of reprogramming factors, the use of EBNA-1 for episomal maintenance, and cultural conditions to enhance establishment efficiency while maintaining the safety advantages of non-integrating vectors
3Productivity
If p53 function is suppressed to improve iPS cell establishment efficiency, then efficiency is improved, but tumorization risk increases
Solution Approach 1:
The patent temporarily suppresses p53 function only during the reprogramming phase when it is necessary to overcome cellular barriers to pluripotency induction, then removes or inactivates the p53 suppression mechanism before transplantation, thereby achieving high efficiency while minimizing tumorization risk through controlled temporal expression
Solution Approach 2:
The patent implements periodic or transient p53 suppression rather than permanent suppression, using inducible systems or temporary expression of p53 inhibitors during critical reprogramming windows, then allowing p53 function to be restored in the resulting iPS cells to maintain safety
4Ease of operation
If blood cells are used as somatic cell source for iPS cell production, then noninvasive procurement is achieved, but establishment efficiency is low
Solution Approach 1:
The patent optimizes multiple parameters including the use of Glis1 as an additional reprogramming factor, EBNA-1-mediated episomal replication, and specialized culture conditions for blood-derived cells to overcome the low efficiency barrier and enable practical clinical application of noninvasively obtained iPS cells
Data Source
AI summary
The present invention provides a production method of iPS cell, including a step of introducing the following (1) and (2):(1) an episomal vector containing a nuclear reprogramming factor; and(2) an episomal vector containing EBNA-1, which is different from (1),into a somatic cell, as well as a method for improving iPS cell establishment efficiency. The present invention also provides an agent for improving iPS cell establishment efficiency, which contains an episomal vector containing a nucleic acid encoding EBNA-1, and a kit for producing an iPS cell further containing an episomal vector containing a nucleic acid encoding a nuclear reprogramming factor.